| 摘要 |
FIELD: medicine. SUBSTANCE: the present innovation deals with therapeutic methods to improve regional myocardial circulation during postischemic reperfusion, and, also, either prevent or minimize tissue lesions associated with postischemic perfusion. Indication mentioned is performed due to injecting composition containing pharmacologically acceptable Factor VII that has got , at least, one modification in his catalytic center which highly inhibits the capacity of modified Factor VII to activate plasmic Factor X or IX. EFFECT: higher efficiency of therapy. 18 cl, 11 dwg, 20 ex, 22 tbl |
